Oxford Biomedica's long-awaited OXB-102 deal did not disappoint Jefferies, but analysts felt the share price was up with events.
Tate & Lyle: Jefferies downgrades to hold with a target price of 700p.
Newspaper share tips from the Sunday Times on Oxford BioMedica, Sunday Telegraph on Avast and Mail on Sunday on Savannah Resources.
Gene and cell therapy group Oxford BioMedica has entered into an exclusive worldwide licensing agreement with Nasdaq-listed Axovant Sciences that will see the pair develop and commercialise OXB-102, a gene therapy for Parkinson's disease developed by the London-listed group.
Gene and cell therapy group Oxford BioMedica has seen Norvatis' chimeric antigen receptor T cell therapy, Kymriah, gain approval from the US Food and Drug Administration for intravenous infusion for its second indication, providing it with a significant boost.
Oxford Biomedica intends to raise approximately £20.5m by way of a conditional placing of ordinary shares to raise money for expansion of bioprocessing facilities, the company said on Friday.
Gene and cell therapy group Oxford BioMedica announced on Thursday that it has completed a major new collaboration and licence agreement with Bioverativ, for the development and manufacture of lentiviral vectors to treat haemophilia.
Oxford Biomedica received a boost as Novartis announced that it has filed for approval of its Kymriah drug for a second blood cancer indication.
AIM-listed pharmaceutical Oxford BioMedica's RetinoStat, the first ocular lentiviral gene therapy to be administered in humans, demonstrated a "favourable safety profile with no serious adverse events" in its phase one study.
Biopharmaceutical company Oxford Biomedica plans to raise £8.1m in a placing of 128.4m shares at 6.3p with new and existing investors.
Gene and cell therapy company Oxford Biomedica has signed a 'transformational' new contract with Novartis worth up to $90m over the next three years.
British American Tobacco: Goldman Sachs reduces target price from 3530p to 3250p downgrading to sell.
Ashmore Group: Jefferies ups target price from 375p to 400p and keeps a buy recommendation. JP Morgan lowers target price from 351p to 345p and reiterates a neutral rating.
Losses widen in challenging year; Clinical trials suspended for five months; Making solid progress throughout pipeline
Shares in Oxford BioMedica jumped after French and US regulators gave their approval for the biopharmaceutical group to resume recruitment for trials of three potential eye medicines it is developing with France's Sanofi.
A round-up of the biggest director deals today so far.
African Minerals: Deutsche Bank cuts target price from 550p to 450p and retains a buy recommendation. Citi lowers target price from 380p to 320p keeping a buy recommendation.
Gene therapy specialist Oxford Biomedica has been awarded a significant grant to help improve its supply chain.